CIK 0001819790 · Large accelerated filer
Tarsus Pharmaceuticals, Inc.
Sign in to watch- Ticker
- TARS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 814717861
- Phone
- (949) 409-9820
- Business address
- 15440 LAGUNA CANYON ROAD, IRVINE, CA, 92618
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,192,759
- in 6 filings, $5.2M under 10b5-1 plans
Net −$5,192,759. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-05 | Whitfield Dianne C. Chief Human Resources Officer | Grant or award · Stock Option (right to buy) | +27,310 | 27,310 | ||
| 2026-03-05 | Whitfield Dianne C. Chief Human Resources Officer | Grant or award · Restricted Stock Units | +17,161 | 17,161 | ||
| 2026-03-05 | Azamian Bobak R. President/CEO and Board Chair | Grant or award · Stock Option (right to buy) | +96,723 | 96,723 | ||
| 2026-03-05 | Azamian Bobak R. President/CEO and Board Chair | Grant or award · Restricted Stock Units | +60,776 | 60,776 | ||
| 2026-03-05 | Neervannan Seshadri Chief Operating Officer | Grant or award · Stock Option (right to buy) | +27,310 | 27,310 | ||
| 2026-03-05 | Neervannan Seshadri Chief Operating Officer | Grant or award · Restricted Stock Units | +17,161 | 17,161 | ||
| 2026-03-05 | Mottiwala Aziz Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +30,724 | 30,724 | ||
| 2026-03-05 | Mottiwala Aziz Chief Commercial Officer | Grant or award · Restricted Stock Units | +19,306 | 19,306 | ||
| 2026-03-05 | Farrow Jeffrey S See Remarks | Grant or award · Stock Option (right to buy) | +30,724 | 30,724 | ||
| 2026-03-05 | Farrow Jeffrey S See Remarks | Grant or award · Restricted Stock Units | +19,306 | 19,306 | ||
| 2026-03-04 | Neervannan Seshadri Chief Operating Officer | Sale 10b5-1 | −8,366 | $76.67 | $641K | 70,817 |
| 2026-02-18 | PYOTT DAVID E I Director | Grant or award · Stock Option (right to buy) | +5,893 | 5,893 | ||
| 2026-02-18 | PYOTT DAVID E I Director | Grant or award · Restricted Stock Units | +3,729 | 3,729 | ||
| 2026-01-02 | Whitfield Dianne C. Chief Human Resources Officer | Sale 10b5-1 | −5,715 | $80.09 | $458K | 33,243 |
| 2026-01-02 | Whitfield Dianne C. Chief Human Resources Officer | Sale 10b5-1 | −8,122 | $80.71 | $656K | 25,121 |
| 2026-01-02 | Whitfield Dianne C. Chief Human Resources Officer | Sale 10b5-1 | −835 | $81.90 | $68K | 24,286 |
| 2026-01-02 | Whitfield Dianne C. Chief Human Resources Officer | Sale 10b5-1 | −893 | $82.93 | $74K | 23,393 |
| 2025-12-24 | Azamian Bobak R. President/CEO and Board Chair | Sale 10b5-1 | −5,443 | $82.41 | $449K | 858,548 |
| 2025-12-24 | Azamian Bobak R. President/CEO and Board Chair | Sale 10b5-1 | −557 | $83.54 | $47K | 857,991 |
| 2025-12-16 | Whitfield Dianne C. Chief Human Resources Officer | Sale 10b5-1 | −7,397 | $80.10 | $592K | 38,958 |
Page 7 of 13 · 257 trades